Thursday, 30 April 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 30 April 2026
News

Next up: Ozempic pills for kids

Posted 30 April 2026 AM

An Ozempic pill for kids is one step closer, after Novo Nordisk announced positive topline results this month from a phase 3a trial evaluating oral semaglutide for type 2 diabetes in children and adolescents aged 10-17.

Oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c (a measure of blood sugar control) by 0.83 per cent versus placebo in the Pioneer Teens trial and showed a well-tolerated safety profile in line with previous semaglutide trials, Novo reported.

To see the whole article, please login

Popular

Pharma off target, doctors say
Big Pharma goes under the hammer
PBAC greenlights new drugs
High-flyers on the move in pharma
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home